Gene therapy of lung cancer

Seminars in Surgical Oncology

Volumn 21, Issue 3, 2003, Pages 196-204

  Daniel, Jonathan C ^a   Smythe, W Roy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Apoptosis; bcl 2; Clinical trials; Gene therapy delivery; Gene therapy vectors; Growth factors; p53; Prodrug therapy; Thoracic malignancies; Tumor suppressor genes

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ADENOVIRUS VECTOR; ADVEXIN; BEVACIZUMAB; CISPLATIN; GANCICLOVIR; LIPOSOME; PROTEIN BCL 2; PROTEIN P53; RETROVIRUS VECTOR; SCH 58500; THYMIDINE KINASE; TRIMETHYLAMMONIUM SALT DERIVATIVE; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COMPUTER ASSISTED DRUG THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DNA VECTOR; DRUG DELIVERY SYSTEM; DYSPNEA; GENE DELIVERY SYSTEM; GENE THERAPY; GENETIC MANIPULATION; GROWTH INHIBITION; HERPES SIMPLEX VIRUS; HUMAN; HYPOXIA; LUNG CANCER; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; META ANALYSIS; MOLECULAR GENETICS; MULTIMODALITY CANCER THERAPY; NONVIRAL GENE DELIVERY SYSTEM; PNEUMOTHORAX; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURVIVAL RATE; THORAX TUMOR; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM;

GENE THERAPY; GENES, P53; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PRODRUGS;

EID: 0141954118     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/ssu.10038     Document Type: Review

References (83)

1. Lederberg J: "DNA breakthrough points way to therapy by virus. " Washington Post; 13 January 1968.
2. Lederberg J: An early history of gene transfer and therapy. Hum Gene Ther 1994;5:469-480.
3. Culver KW, Osborne WR, Miller AD, et al: Correction of ADA deficiency in human T lymphocytes using retroviral-mediated gene transfer. Transplant Proc 1991;23:170-171.
4. American Cancer Society: Cancer facts and figures 2003. Website. http://www.cancer.org.
5. Ries LAG, Eisner MP, Kosary CL, et al. (eds): "SEER Cancer Statistics Review, 1975-2000." Bethesda, MD: National Cancer Institute; 2003.
6. Hung J, Kishimoto Y, Sugio K, et al: Allele specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA 1995;273:558-563.
7. Mori N, Yokota J, Oshimura M, et al: Concordant deletions of chromosome 3p and loss of heterozygosity for chromosomes 13 and 17 in small cell lung carcinoma. Cancer Res 1989;49:5130-5135.
8. Salgia R, Skarin AT: Molecular abnormalities in lung cancer. J Clin Oncol 1998;16:1207-1217.
9. Chiba I, Takahashi T, Nau MM, et al: Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene 1990;5:1603-1610.
10. Takahashi T, Nau MM, Chiba I, et al: p53: a frequent target for genetic abnormalities in lung cancer. Science 1989;246(4929): 491-494.
11. Craig C, Kim M, Ohri E, et al: Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene 1998;16:265-272.
12. Joshi US, Chen YQ, Kalemkerian GP, et al: Inhibition of tumor cell growth by p21 WAF1 adenoviral gene transfer in lung cancer. Cancer Gene Ther 1998;5:183-191.
13. Naruse I, Hoshino H, Dobashi K, et al: Over-expression of p27kip1 induces growth arrest and apoptosis mediated by changes of pRb expression in lung cancer cell lines. Int J Cancer 2000;88:377-383.
14. Antelman D, Machemer T, Huyghe BG, et al: Inhibition of tumor cell proliferation in vitro and in vivo by exogenous p110RB, the retinoblastoma tumor suppressor protein. Oncogene 1995;10:697-704.
15. Sozzi G, Tornielli S, Tagliabue E, et al: Absence of FHIT protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 1997;57:5207-5212.
16. Tseng JE, Kemp BL, Khuri FR, et al: Loss of FHIT is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 1999;59:4798-4803.
17. Ji L, Fang B, Yen N, et al: Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999;59:3333-3339.
18. Mhashilkar AM, Schrock RD, Hindi M, et al: Melanoma differentiation associated gene-7 (MDA-7): a novel anti-tumor gene for cancer gene therapy. Mol Med 2001;4:271-282.
19. Saeki T, Mhasilkar AM, Swanson X, et al: Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene 2002;21:4558-4566.
20. Fontanini G, Lucchi M, Vignati S, et al: Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997;89:881-886.
21. Fontanini G, Vignati S, Boldrini L, et al: Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997;3:861-865.
22. Giatromanolaki A, Koukourakis MI, Kakolyris S, et al: Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 1998;4:3017-3024.
23. Devore RF, Fehrenbacker RS, Herbst RS, et al: A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLS [Abstract]. Proc Am Soc Clin Oncol 2000;19:485a.
24. Senger DR, Galli SJ, Dvorak AM, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219(4587):983-985.
25. Zebrowski BK, Yano S, Wenbiao L, et al: Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999;5:3364-3368.
26. Selvaggi G, Scagliotti GV, Torri V, et al: HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival. Cancer 2002;94:2669-2674.
27. Kern JA, Schwartz DA, Nordberg JE, et al: p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990;50:5184-5187.
28. Casalini P, Menard S, Malandrin SM, et al: Inhibition of tumorigenicity in lung adenocarcinoma cells by c-erbb2 antisense expression. Int J Cancer 1997;72:631-636.
29. Fang K, Chen MH: Transfection of anti-sense complementary DNA of human epidermal growth factor receptor attenuates the proliferation of human non-small cell lung cancer cells. Int J Cancer 1999;81:471-478.
30. Azzoli CG, Krug LM, Miller VA, et al: Trastuzumab in the treatment of non-small cell lung cancer. Semin Oncol 2002;29(1 Suppl 4):59-65.
31. Slebos RJ, Kibbelaar RE, Dalesio O, et al: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323:561-565.
32. Mukhopadhyay T, Tainskym Cavender AC, Roth JA: Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 1991;51:1744-1748.
33. Alemany R, Ruan S, Kataoka M, et al: Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Cancer Gene Ther 1996;3:296-301.
34. Zhang Y, Nemunaitis J, Tong A: Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells. Mol Biotechnol 2000;15:39-49.
35. Reed J: Double identity for proteins of the Bcl-2 family. Nature 1997;387(6356):773-776.
36. Pezzella F, Turley H, Kuzu I, et al: Bcl-2 protein in non small-cell carcinoma. N Engl J Med 1993;329:690-694.
37. Soini Y, Kinnula V, Kaarteenhaho WR, et al: Apoptosis and expression of apoptosis-regulating proteins bcl-2, mcl-1, bclx and bax in malignant mesothelioma. Clin Cancer Res 1999;5:3508-3515.
38. Leech SH, Olie RA, Gautschi O, et al: Induction of apoptosis in lung-cancer cells following bcl-xl anti-sense treatment. Int J Cancer 2000;86:570-576.
39. Gautschi O, Tschopp S, Olie RA, et al: Activity of a novel bcl-2/bcl-xl bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 2001;93:463-471.
40. Smythe WR, Mohuiddin I, Ozvaran M, Cao X: Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J Thorac Cardiovasc Surg 2002;123:1191-1198.
41. Mohiuddin I, Cao X, Fang B, et al: Significant augmentation of proapoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma. Cancer Gene Ther 2001;8:547-554.
42. Pataer A, Smythe WR, Yu R, et al: Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines. J Thorac Cardiovasc Surg 2001;121:61-67.
43. Kagawa S, He C, Gu J, et al: Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001;6:3330-3338.
44. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986;46:5276-5281.
45. Smythe WR: Prodrug/Drug sensitivity gene therapy: current status. Curr Oncol Rep 2000;2:17-22.
46. Culver KW, Ram Z, Wallbridge S, et al: In vivo gene transfer with retroviral vector producer cells for the treatment of experimental brain tumors. Science 1992;256(5063):1550-1552.
47. Smythe WR, Hwang HC, Amin KM, et al: Use of recombinant adenovirus to transfer the herpes simplex thymidine kinase gene (HSVtk) to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 1994;54:2055-2059.
48. Smythe WR, Hwang HC, Elshami AA, et al: Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995;222:78-86.
49. Hwang HC, Smythe WR, Elshami AA, et al: Gene therapy using adenovirus carrying the herpes simplex thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995;13:7-16.
50. Sterman DH, Treat J, Litzky LA, et al: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998;9:1083-1092.
51. Wiewrodt R, Kunjlata A, Kiefer M, et al: Adenovirus-mediated gene transfer of enhanced herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther 2003;10:353-364.
52. Kurdow R, Boehle AS, Haye S, et al: Ganciclovir prodrug therapy is effective in a murine xenotransplant model of human lung cancer. Ann Thorac Surg 2002;73:905-910.
53. Gautum A, Densmore CL, Waldrep JC: Inhibition of experimental lung metastasis by aerosol delivery of PEI-p53 complexes. Mol Ther 2000;2:318-323.
54. Kubba S, Adak S, Shiller J, et al: Phase I trial of Adenovirus p53 in bronchioalveolar cell lung carcinoma (BAC) administered by bronchoalveolar lavage [Abstract]. Proc Am Soc Clin Oncol 2000;19:487a.
55. Osaki T, Hanagiri T, Nakanishi R, et al: Bronchial arterial infusion is an effective therapeutic modality for centrally located early-stage lung cancer. Chest 1999;115:1424-1428.
56. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348:255-256.
57. Miller DG, Adam MA, Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990;10:4239-4242.
58. Thomas C, Ehrhardt A, Kay M: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003;4:346-358.
59. Burns JC, Friedmann T, Driever W, et al: Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammallian cell. Proc Natl Acad Sci USA 1993;90:8033-8037.
60. Morsy MA, Caskey CT: Expanded-capacity adenoviral vectors - the helper-dependent vectors. Mol Med Today 1999;5:18-24.
61. Fisher KD, Stallwood Y, Green NK, et al: Polymer-coated adenovirus permits efficient retargeting and evades neutralizing antibodies. Gene Ther 2001;8:341-348.
62. Hemminki A, Kanerva A, Liu B, et al: Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 2003;63:847-853.
63. Chesnoy S, Huang L: Structure and function of lipid-DNA complexes for gene delivery. Annu Rev Biophys Biomol Struct 2000;29:27-47.
64. Mahato RI, Kawabata K, Takakura Y, Hashida M: In vivo disposition characteristics of plasmid DNA complexed with cationic liposomes. J Drug Target 1995;3:149-157.
65. Templeton NS, Lasic DD, Frederik PM, et al: Improved DNA: Liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 1997;15:547-652.
66. Ramesh R, Saeki T, Templeton NS, et al: Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther 2001;3:337-350.
67. Tousignant JD, Gates AL, Ingram LA, et al: Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum Gene Ther 2000;11:2493-2513.
68. Tan Y, Li S, Pitt BR, Huang L: The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum Gene Ther 1999;10:2153-2161.
69. Zou Y, Zong G, Ling YH, Perez-Soler R: Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer. Cancer Gene Ther 2000;7:683-696.
70. Chen J, Wu X, Lin J, Levine AJ: Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 1996;16:2445-2452.
71. Suzuki H, Takahashi T, Kuoishi T, et al: p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res 1992;52:734-736.
72. Fugiwara T, Cai DW, Georges RN, et al: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994;86:1458-1462.
73. Zhang WW, Fang X, Mazur W, et al: High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994;1:5-13.
74. Swisher SG, Roth JA: Adenoviral p53 gene therapy strategies in non-small cell lung cancer. In Choy H (ed): "Chemoradiation in cancer therapy." New Jersey: Humana Press; 2002; p. 351-360.
75. Roth JA, Nguyen D, Lawrence DD, et al: Retrovirus-mediated wild-type p53 transfers to tumors of patients with lung cancer. Nat Med 1996;2:985-991.
76. Shuler M, Rochlitz C, Horowitz JA, et al: A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 1998;9:2075-2082.
77. Swisher SG, Roth J, Nemunaitis J, et al: Adenovirus-Mediated p53 gene transfer in advanced non-small cell lung cancer. J Natl Cancer Inst 1999;91:763-771.
78. Lowe SW, Ruley HE, Jacks T, Housman DE: P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-967.
79. Rusch V, Klimstra D, Venkatraman E, et al: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995;55:5038-5042.
80. Fujiwara T, Grimm EA, Mukhopadhyay T, et al: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54:2297-2291.
81. Nemunaitis J, Swisher SG, Timmons T, et al: Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000;18:609-622.
82. Shuler M, Herrmann R, Jacques LP, et al: Adenovirus-Mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small cell lung cancer: results of a multicenter Phase II study. J Clin Oncol 2001;19:1750-1758.
83. Swisher SG, Roth JA, Komaki R, et al: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003;9:93-101.